United States

Back to map

Showing 291-300 of 333 grants

Title Institution Researcher Program Duration Total Award Amount
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes Regents of the University of Colorado Jessica Kendrick Improving Lives 01-October-2022 to 30-September-2025 $899.235,00
Understanding the role of scaffold microarchitecture on survival and function of stem cell-derived beta cells Brown University Tejal Desai Cures 01-October-2022 to 30-September-2025 $474.761,58
Avera eCare School Health T1D Demonstration Project Avera McKennan Christine Hockett Improving Lives 01-November-2021 to 31-July-2025 $4.000.979,73
Ultrafast Insulin-Pramlintide Co-formulations Stanford University Eric Appel Improving Lives 01-September-2022 to 31-August-2025 $795.000,00
Local delivery of beta-cell survival factors and immunomodulators to enable highly efficient immunosuppression-free islet transplantation Brown University Tejal Desai Cures 01-October-2022 to 01-October-2025 $714.857,80
Optimization of fast-acting venom insulins as therapeutic candidates for T1D University of Utah Helena Safavi Improving Lives 01-September-2022 to 31-August-2025 $890.372,53
Deep Learning-based Analyses of Pancreatic Islet Beta-Cell Heterogeneity and MRI Pancreas Volume as Biomarkers to Improve Understanding of Type 1 Diabetes Progression University of Florida Sarah Kim Cures 01-June-2022 to 31-May-2026 $750.000,00
A Magnetic Pumping Mechanism for Miniaturized High-Accuracy External Insulin Pump Stanford University Renee Zhao Improving Lives 01-May-2022 to 30-April-2025 $676.000,00
Ketone Monitoring in T1D: Effect of SGLT2i during Usual Care and with Insulin Deficiency Washington University Janet McGill Improving Lives 01-September-2022 to 31-August-2024 $359.651,69
Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes iTolerance, Inc. Camillo Ricordi Cures 01-June-2022 to 31-August-2025 $850.000,00